Immunovant (IMVT) Preferred Stock Liabilities (2019)
Immunovant's (IMVT) quarterly Preferred Stock Liabilities came in at $108.4 million in Q3 2019, little changed on a QoQ basis from $108.3 million in Q2 2019.
Immunovant (IMVT) Preferred Stock Liabilities (2019) Analysis & Trends
Immunovant (IMVT) has 1 years of Preferred Stock Liabilities data on file, last reported at $108.4 million in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Immunovant | 8.63 Bn | 7.83 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 108.42 Mn |
| Jun 30, 2019 | 108.30 Mn |